Form 4: Esquire Financial Director Sells $477K in Company Stock Under Pre-Planned Arrangement

Selig Zises, a Director at Esquire Financial Holdings, Inc., reported the sale of 5,000 shares of common stock on July 31, 2025, for approximately $476,924, executed under a Rule 10b5-1 trading plan.

Summary

• Selig Zises, a Director of Esquire Financial Holdings, Inc. (ESQ), reported the sale of 5,000 shares of common stock.
• The transactions occurred on July 31, 2025, at prices ranging from $95.20 to $95.675 per share, totaling approximately $476,924.
• The sales were executed as follows: 1,000 shares at $95.20, 1,000 shares at $95.25, 1,500 shares at $95.3078, and 1,500 shares at $95.675.
• The transactions were made pursuant to a Rule 10b5-1(c) trading plan.
• Following these transactions, Selig Zises beneficially owns a total of 170,097 shares of common stock, comprising 14,963 shares held directly and 155,134 shares held indirectly through a profit sharing plan, trusts, and an L.P.
• Indirect holdings include 29,501 shares by a profit sharing plan, 87,533 shares by a trust (after the reported sales from the trust), 25,500 shares as trustee for a trust, and 12,600 shares by an L.P.
• The filing also details several tranches of restricted stock that will vest in equal annual installments commencing on December 19, 2023, December 16, 2024, December 9, 2025, December 19, 2026, December 3, 2027, and December 15, 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be perceived negatively, the disclosure that the sales were made under a Rule 10b5-1 plan mitigates concerns that the sales are based on adverse non-public information, making them an expected part of an insider's financial planning.

Positives

• The stock sales were conducted under a Rule 10b5-1(c) plan, indicating that the transactions were pre-scheduled and not based on new, non-public information, which can mitigate concerns about insider selling.

Negatives

• A Director's sale of common stock reduces insider ownership, which can sometimes be perceived as a slight negative signal by investors, even if pre-planned.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, which focuses solely on insider transactions.

Future Outlook

The filing does not provide forward-looking statements regarding the company's financial performance or strategic direction. It only details future vesting schedules for restricted stock held by the reporting person.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information on broader industry trends or competitive landscape for Esquire Financial Holdings, Inc. (ESQ), which operates in the financial services sector.

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns about its implications for the company's future performance.

Next Steps

• Future vesting of restricted stock held by Selig Zises will occur in three equal annual installments commencing on December 19, 2023, December 16, 2024, December 9, 2025, December 19, 2026, December 3, 2027, and December 15, 2027.

Key Dates

Recommendation

The sale by a director, while notable, was conducted under a pre-arranged 10b5-1 plan, which suggests it is part of routine financial management rather than a signal of deteriorating company fundamentals. Without additional information on company performance or broader market trends, this single transaction does not warrant a change from a 'hold' recommendation.

Keywords

Esquire Financial Holdings, ESQ, Insider Trading, Form 4, Stock Sale, Director, Selig Zises, 10b5-1 Plan, Common Stock, Restricted Stock